16.02.2018 08:00:00 CET

Notice of Nexstim Plc 2017 Full Year Results

Company announcement, Helsinki, 16 February 2018, at 9 am

Notice of Nexstim Plc 2017 Full Year Results

Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company"), a medical technology company developing and marketing pioneering navigated non-invasive brain stimulation systems for both therapeutic and diagnostic applications, will announce its full year results for the year ended 31 December 2017 on Wednesday 28 February 2018 at 9.00 am Finnish time.

A conference call for analysts, investors and media will take place at 15:00 Finnish time (EET) on Wednesday 28 February 2018, hosted by Martin Jamieson, Chairman of the Board and CEO, and Mikko Karvinen, CFO, who will present the financial and operational results followed by a Q&A session.

The dial-in numbers for the conference call are:
Finland: +358 (0) 800 914672
Sweden: +46 (0) 20 089 6377
UK: +44 (0) 20 3003 2666
US: + 1 866 966 5335
Standard International: +44 (0) 20 3003 2666

The call password is Nexstim

NEXSTIM PLC
Martin Jamieson, Chairman and CEO

Further information is available on the website www.nexstim.com or by telephone:

Nexstim                                          +447715163942
Martin Jamieson, Chairman and CEO martin.jamieson@nexstim.com
                                                                                                                                                      
UB Securities Oy (Certified Adviser)  +358 (0)9 2538 0246

Citigate Dewe Rogerson             +44 (0)207 2822949
David Dible/Isabelle Andrews/Shabnam Bashir david.dible@citigatedewerogerson.com

About Nexstim Plc
Nexstim is a medical technology company developing and marketing pioneering navigated non-invasive brain stimulation systems for both therapeutic (NBTŪ system) and diagnostic (NBS system) applications. Nexstim's NBS system is the only FDA cleared and CE marked system based on navigated Transcranial Magnetic Stimulation (nTMS) for the pre-surgical mapping of the speech and motor cortices of the brain. Based on the same technology platform, the Company has developed the Navigated Brain Therapy (NBTŪ) which is CE marked in Europe for the treatment of stroke, major depression and chronic neuropathic pain.

Nexstim has received clearance from the FDA for marketing and commercial distribution of its NBTŪ system for the treatment of Major Depressive Disorder (MDD) and looks forward to introducing the NBTŪ system for this important indication during H1 2018.

The NBTŪ system is currently in a 60 patient, supplemental Phase III study, E-FIT trial, for its use in stroke rehabilitation. The trial is expected to complete in Q2 2018, allowing Nexstim to file for FDA clearance. FDA clearance would allow Nexstim to start marketing and selling its NBTŪ system for stroke rehabilitation in the USA.

Nexstim shares are listed on the Nasdaq First North Finland and Nasdaq First North Sweden. For more information please visit www.nexstim.com

Notice of Nexstim Plc 2017 Full Year Results